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Essential tremor (ET) is a common neurodegenerative disorder that is characterized by a postural or motion tremor. Despite a strong
genetic basis, a gene with rare pathogenic mutations that cause ET has not yet been reported. We used exome sequencing to implement
a simple approach to control for misdiagnosis of ET, as well as phenocopies involving sporadic and senile ETcases. We studied a large ET-
affected family and identified a FUS p.Gln290*mutation as the cause of ET in this family. Further screening of 270 ETcases identified two
additional rare missense FUS variants. Functional considerations suggest that the pathogenic effects of ET-specific FUS mutations are
different from the effects observed when FUS is mutated in amyotrophic lateral sclerosis cases; we have shown that the ET FUS nonsense
mutation is degraded by the nonsense-mediated-decay pathway, whereas amyotrophic lateral sclerosis FUS mutant transcripts are not.Introduction
Essential tremor (ET [MIM 190300]) is a neurodegenerative
disorder that is considered to be one of the most common
adult-onset movement disorders.1,2 A recent meta-analysis
that used population-based studies (n ¼ 28) estimated that
the pooled prevalence of ET (at all ages) was 0.9%2 and
found that there is an increasing prevalence as age
increases (the prevalence is 4.6% for individualsR 65 years
old).2 In 1998, the Movement Disorder Society created
a consensus statement defining ET as a bilateral, mainly
symmetrical postural or motion tremor that primarily
affects the upper limbs.3 The heterogeneity of tremors
(including their clinical expression, therapeutic response,
pathology, and etiology) has, however, been suggested to
underlie the common misdiagnosis of ET; 37%–50% of
individuals previously diagnosed with ET are reportedly
misdiagnosed.4,5
There are three subtypes of ET—hereditary, sporadic, and
senile6—and most studies indicate that ET is a hereditary
disorder in 50%–70% of affected individuals (and presum-
ably has autosomal-dominant inheritance).7 Studies of
large ET-affected families have shown that a family history
of ET typically means an early age of onset, and the pheno-
type is usually fully penetrant by the age of 65 years. Thus,
a hereditary-ET-affected family is defined as having at
least two immediate family members affected with the
disease and at least two family members diagnosed before
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The AmericLinkage studies on families have identified three ET-asso-
ciated loci (ETM1 [MIM 190300], ETM2 [MIM 602134],
and ETM3 [MIM 611456]), but no gene with causative
mutations has been reported.8–10 A common variation,
c.312G>A, in dopamine D3 receptor (DRD3 [MIM
126451]) within the ETM1 locus has been suggested to be
a susceptibility factor for ET.11 However, this association
has not been consistently replicated. More recently,
common sequence variants in LINGO1 (MIM 609791)
have been associated with ET,12 but the significance of
these findings remains unclear as well. Exome sequencing
has recently been validated as a method of identifying rare
coding variants that cause monogenic disease.13 This
approach allows the use of only a few selected affected
individuals and controls for the identification of disease-
associated genes, which has been noted to be particularly
beneficial when large families are not available for linkage
analysis.13 Many large ET-affected families have been re-
ported in the literature, but their usage in classical
linkage-based gene-discovery efforts has been hindered
by a number of factors. First, ET is a disorder that has
been reported to be overdiagnosed;4,5 therefore, it is very
likely that some unaffected members in large families are
misdiagnosed as affected individuals, which would hinder
linkage studies. Second, the high prevalence of ET
increases the risk that a sporadic or senile case (or cases)
exists in large families; such cases would be phenocopies
that would also hinder linkage studies. Therefore, we
hypothesized that exome sequencing could help identifyontre´al Research Center, Universite´ de Montre´al, Montre´al, QC H2L 2W5,
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Figure 1. A Schematic of ET Variants
within FUSrare penetrant variants that cause hereditary ET through
the selection of a small number of ‘‘definitely’’ affected
individuals (with an early age of onset) from ET-affected
families; this would thus minimize the clinical barriers
associated with ET.Subjects and Methods
A detailed version of this study’s methodology is supplied in the
Supplemental Data, available online. In brief, one ET-affected
family, FET1, was chosen for study (Figure S1). During clinical
assessment, ET was diagnosed as either ‘‘definite,’’ ‘‘probable,’’ or
‘‘possible’’3,14 (Figure S2). The genomic DNA from four individuals
with a ‘‘definite’’ ET diagnosis and an age of onset before 40 years
and from a clinically unaffected married-in family member was
captured with Agilent SureSelect all exome kits and sequenced
with an Applied Biosystems SOLiD apparatus. Ethics approval
for the recruitment and genetic analysis of ET-affected individuals
and their families was granted by the following institutes: the
Centre de recherche du Centre hospitalier de l’Universite´ de
Montre´al (project ND043076), the Centre hospitalier affilie´ uni-
versitaire de Que´bec (project PEJ-280), and the Sainte-Justine
University Hospital Center (project 2352).Results
Exome Sequencing
After a list of exome-sequencing variants was generated for
each family member, segregation analysis revealed a list of
six exome-sequencing variants (three synonymous, two
nonsynonymous, and one nonsense) that were shared
exclusively by ‘‘definitely’’ affected individuals from family
FET1 and that had a sequencing quality score greater than
50; capture efficiency for each individual was comparable
between individuals (Figure S3 and Table S1). After Sanger314 The American Journal of Human Genetics 91, 313–319, August 10, 2012sequencing, only one of those six
variants proved to be legitimate—a
nonsense mutation in FUS/TLS (fused
in sarcoma/translocated in liposar-
coma [MIM 137070]) (Figure 1 and
Table 1). This variant, c.868C>T
(in exon 9), corresponding to a stop
mutation at p.Gln290* (RefSeq
accession number NM_004960.3),
had an average sequencing quality
of 54.7, coverage of 1333, and muta-
tion frequency of 36%. Furthermore,
p.Gln290* was not detected in a
cohort of 450 ethnically-matched
control individuals (Table 1). Addi-
tionally, no truncating mutation has
been identified in the ~5,000 exomesfor which variants are presently listed in the National
Heart, Lung, and Blood Institute (NHLBI) Grand Opportu-
nity (GO) Exome Sequencing Project (ESP) database. In
fact, this mutation is only the third nonsense mutation
ever reported in FUS; the other two (p.Arg495* and
p.Gln519*) cause amyotrophic lateral sclerosis (ALS [MIM
608030]).15,16 Amino acid 290 is located in the nuclear
export signal (NES) motif of FUS (Figure 1).
Segregation Analysis of FUS c.868C>T in FET1 Family
Members
All ‘‘definitely’’ and ‘‘probably’’ affected individuals from
FET1 carried FUS c.868C>T (Figure S1 and Table S2).
However, only 54% (7/13) of ‘‘possibly’’ affected individ-
uals had the mutation. Of the seven ‘‘possibly’’ affected
individuals with the mutation, three had an onset before
40 years of age and four had an unknown age of onset.
Overall, the age of disease onset of individuals who
harbored the mutation was variable and life expectancy
was normal; notably, numerous individuals were over the
average age of ALS onset and had no symptoms of the
disease (Figure S1 and Table S2). Out of 13 clinically unaf-
fected individuals, one (individual III:38, who was 24 years
of age at the time of clinical observation; Figure S1) was
mutation positive and might harbor a nonpenetrant
variant (Figure S1 and Table S2).
FUS Screening in an ET Cohort
After screening of 270 ET cases for FUS coding variants,
two rare missense variants were detected (Table 1). A
c.1292C>T (p.Pro431Leu) variant was observed in exon
12 from a case with familial ET and was absent from our
control cohort (Table 1). Additional family members were
not available for segregation analysis. The proline at posi-
tion 431 is a highly conserved amino acid (Figure S4)
Table 1. Rare FUS Variants that Have Been Identified in ET-Affected Individuals
Identification Exon
Mutation Nomenclature Ethnically Matched Control Cohort
Coding
(NM_004960.3) Genomic (hg19) Protein
Individuals
Screened
Alleles with
Variant
Allele
Frequency
Through exome
sequencing
exon 9 c.868C>T chr16: g.31200479C>T p.Gln290* 450 0/900 0%
During the subsequent
screening of an
ET cohort
exon 6 c.646C>T chr16: g.31196382C>T p.Arg216Cys 450 1/900 0.1%
exon 12 c.1292C>T chr16: g.31201719C>T p.Pro431Leu 450 0/900 0%that is located in the zinc finger domain of FUS (Figure 1),
and bioinformatics prediction software programs Muta-
tionTaster, SIFT, and Polyphen predict the substitution of
a proline for a leucine to be disease causing, intolerable,
and probably damaging, respectively. Interestingly, this
variant, which is located in the last nucleotide of exon
12, is predicted to affect the splicing donor site of intron
12 (the donor-site score efficiency decreases from 0.90 to
0.61 with the variant). However, no splicing abnormality
was detected with the use of cDNA prepared from lympho-
blastoid cells derived from the affected individual with the
c.1292C>T variant.
In exon 6, a c.646C>T (p.Arg216Cys) variant was de-
tected in two ET cases, one with familial ET and the other
a sporadic case (Table 1). With regard to the familial case,
additional family members were not available for segrega-
tion analysis. A recent study reported this variant in
a sporadic ALS case and not in any of their 500 control
individuals; no comment was made regarding the presence
of a tremor.17 The same report stated that three in silico
prediction programs—PolyPhen, SNAP, and PMUT—pre-
dicted p.Arg216Cys to be damaging.17 SIFT also predicts
this variant to be intolerable, and MutationTaster suggests
that it is disease causing; the arginine at amino acid 216 is
highly conserved (Figure S4) and is located in the glycine-
rich domain (Figure 1). This variant was, however, detected
in our control cohort (1/900 alleles) (Table 1). Additionally,
it did not lead to splicing abnormalities in lymphoblastoid
cells derived from an individual with this variant. Interest-
ingly, this nucleotide variation disrupts a CpG site.
Functional Studies
Overall, the definitive mechanism by which FUS muta-
tions cause ALS remains elusive; therefore, we used lym-
phoblastoid cell lines derived from ET- and ALS-affected
individuals to compare mRNA expression in order to gain
insights into the distinct mechanisms likely to be involved
in the two diseases (Figure 2). Quantitative RT-PCR showed
that the overall expression of FUS in the ET-affected indi-
viduals who carry FUS c.868C>T (p.Gln290*) was lower
than that of ALS-affected individuals with FUS mutations
(Figure 2A); additionally, the expression of FUS in
ET-affected individuals who carry c.868C>T increased
3.6-fold (p value ¼ 0.02) upon treatment with the transla-
tion inhibitor puromycin, an antibiotic that suppresses
nonsense-mediated decay (NMD) and facilitates the obser-The Americvation of mRNA with nonsense mutations18 (Figure 2A).
These observations led to the hypothesis that mutant
mRNA in cells with the ET FUS nonsense mutation is
degraded by the NMD pathway and that ALS FUS mutant
transcripts are not. Of note is that ALS mutations generally
cluster at the 30 end of FUS and would thus probably escape
NMD; in fact, recent observations support the notion that
the NMD pathway is not a major determinant of either
toxicity or expression of ALS FUS mutants.19 To test our
hypothesis, after the lymphoblastoid cells of five ET-
affected individuals who carry the c.868C>T mutation
and three ALS-affected individuals with three different
FUS mutations were treated with puromycin, we prepared
nonquantitative FUS RT-PCR of cDNA from treated and
untreated cells and sequenced the products from each
set. Upon examination of the various sequence traces,
the mutated allele from the ET-affected individuals could
only be observed in cells treated with puromycin
(Figure 2B). This result suggests that a substantial fraction
of ET mutant RNA might be degraded through NMD. In
contrast, the mutated alleles of ALS-affected individuals
were clearly observed in both untreated and puromycin-
treated cells (Figure 2B). This observation prompted us to
quantitatively measure the expression of the two separate
c.868 FUS alleles in cells from the ET-affected individuals.
In the absence of puromycin, the expression of the mutant
RNAwas below the automatic threshold of detection of the
assay (Figure 2C and Figure S5). However, in the presence
of puromycin, the mutant RNA was observed, specifically
at approximately 25% of the level of expression of the
wild-type allele; this level is comparable to the allelic ratios
observed in the sequence traces (Figures 2B and 2C).Discussion
Traditional gene-discovery approaches (linkage studies and
homozygosity mapping) have successfully discovered
causal variants of monogenic disorders over the past two
decades.20 However, not all monogenic disorders accom-
modate well to such studies, and recently, exome
sequencing has been recognized as a way of identifying
rare causal variants for such disorders.13 The exome-
sequencing approach has thus facilitated gene discovery
of monogenic disorders, the majority of which, however,
have an autosomal-recessive mode of inheritance.21an Journal of Human Genetics 91, 313–319, August 10, 2012 315
Figure 2. Expression of FUS mRNA
Carrying ET and ALS Mutations
(A) Lymphoblastoid cells derived from five
ET-affected individuals (individuals II:13,
III:14, IV:6, IV:11, and IV:12 in Figure S1)
who carry the FUS c.868C>T (p.Gln290*)
mutation and from ALS-affected individ-
uals expressing three different FUS muta-
tions (c.1555C>T [p.Gln519*], c.1562G>A
[p.Arg521His], and c.1542-2A>C) were
treatedwith the protein-synthesis inhibitor
puromycin (300 mg for 6 hr). After this,
treated cells were harvested, and total RNA
was prepared (Trizol extraction, Invitrogen)
alongside the total RNA of untreated cells.
Quantitative RT-PCR reactions were then
performed with a Taqman probe specific to
FUS (***p value ¼ 6.47 3 105 [comparing
the difference in mRNA expression in ET
and ALS untreated cells]; **p value ¼ 0.03
[comparing the difference inmRNA expres-
sion in ET and ALS treated cells]). For each
group of affected (ET and ALS) individuals,
the average levels of expression are plotted.
t tests were used for statistics, and error bars
correspond to the standard error of the
mean (SEM).
(B) Standard nonquantitative RT-PCR reactions were prepared with the RNA used in (A) and primers in the flanking exons (or UTRs) of
eachmutation. Amplified cDNAwas sequenced, andwhereas the ALSmutations were seen independently of a puromycin treatment, the
ET mutation could only be seen in puromycin-treated cells.
(C) Quantitative allele-specific expressionmeasurements of the same five FUS c.868C>T ET individuals from above were made with a set
of Taqman custom-designed probes and primers for the wild-type (c.868C) and mutant (c.868T) alleles. After the puromycin treatment,
the expression of the mutant allele became detectable. The specificity of the custom probe for the c.868C>T transcript is demonstrated
in Figure S5. All expression levels were normalized with the human 18S ribosomal RNA (rRNA) gene and were calculated in comparison
to the average level of expression of two healthy controls. t tests were used for statistics, and error bars correspond to SEM.Nonetheless, the adoption of different variant identifica-
tion strategies has allowed the identification of the causa-
tive variants for a smaller number of autosomal-dominant
disorders.22–25 In this study, we report on a modified
genetic approach for overcoming clinical barriers associ-
ated with ET, and this approach has allowed us to identify
FUS mutations that cause ET.
We identified FUS c.868C>T (p.Gln290*) as the patho-
genic variant that causes ET in family FET1. Although we
did not obtain ideal exome-sequence coverage by using
the Applied Biosystems SOLiD technology, we were fortu-
nate to identify this extremely rare nonsense FUS variant.
FUS c.868C>T fully segregated with the disease in individ-
uals with a ‘‘definite’’ and ‘‘probable’’ ET diagnosis. How-
ever, it was only present in 54% of the ‘‘possibly’’ affected
individuals, supporting our initial belief that ET genetic
studies still have to overcome many clinical barriers, such
as distinguishing sporadic phenocopies from the heredi-
tary cases within a family. In fact, past attempts at identi-
fying the mutant gene in FET1 failed as a result of this
manner. During a previous linkage study that was per-
formed on FET1 family members, the highest two-point
LOD score obtained was on chromosome 16 at marker
D16S3034 (Z ¼ 2.73), and haplotype construction showed
segregation of a disease haplotype (Rouleau, unpublished
data). FUS is within this disease region, but a recombina-
tion event in a ‘‘possibly’’ affected individual (individual
IV:10, who does not have the FUS mutation [Figure S1])316 The American Journal of Human Genetics 91, 313–319, August 1was used for reducing the disease region and excluded
FUS as a positional candidate gene.
Two additional rare variants, c.1292C>T (p.Pro431Leu)
and c.646C>T (p.Arg216Cys), were identified in FUS after
screening of a cohort of ET cases. Both variants are highly
conserved and predicted to be pathogenic by bioinfor-
matics software. The substitution of a proline for a leucine
at position 431 was not detected in our control cohort.
Despite the fact that this variant was predicted to have
an effect on splicing, a splicing defect was not apparent
in lymphoblastoid cells of the individual with the
c.1292C>T variant. However, given that it was predicted
to affect the efficiency of the intron 12 donor site by
approximately 30%, perhaps such a marginal decrease
was undetectable in our experiments in which lympho-
blastoid cells were used and only a low level of aberrant
messenger influences the disease onset. An alternative
explanation might be that the predicted splicing defect is
specific, or more frequent, in cells from the nervous system
and can thus not be detected with the material that was
currently available. The c.646C>T variant was detected
in two ET probands but has also been reported in one
sporadic ALS case17 and in one control in our study,
corresponding to a frequency that is plausible for an ET-
causing variant considering the prevalence of ET (0.9%
for all ages). This variant is in exon 6 of FUS and in the
glycine-rich region of FUS. Interestingly, this arginine
residue is one of two FUS arginines that are physiologically0, 2012
dimethylated,17 which is amodification that can be impor-
tant for protein shuttling and signal transduction, particu-
larly in proteins involved in splicing.26 A splicing defect
was not apparent in lymphoblastoid cells of the
c.646C>T mutant, and, again, such an event might also
be specific, or more frequent, in cells from the nervous
system. Furthermore, this variant disrupts a CpG site,
and an epigenetic effect on gene expression (through de-
methylation) could thus possibly explain disease patho-
genesis. Also, methylation of cytosines at CpG sites and
subsequent deamination is a common mechanism of
recurrent mutations and could thus explain the slightly
higher occurrence of c.646C>T in this cohort. Intriguingly,
the lymphoblastoid cells of individuals with each ET
missense variant had a significant lower overall expression
of the FUS mRNA than did those of ALS-affected indi-
viduals with FUS mutations (without treatment, the
c.646C>T p value ¼ 8.88 3 104 and the c.1292C>T
p value ¼ 0.013). They also showed a significant increase
in overall FUS mRNA expression after puromycin treat-
ment: a 2.9-fold increase for c.646C>T (p value ¼ 0.01)
and a 3.2-fold increase for c.1292C>T (p value ¼ 0.04).
These observations are similar to the total expression of
FUS in the c.868C>T mutant cells and need further explo-
ration. Overall, FUS variants appear to be a rare cause of ET
given that they explain, at most, 1.5% of our ET cohort.
Interestingly, FUSmutationswere recognized as a causeof
ALS in 2009;27,28 they explain approximately 4%of familial
cases.29 ALS is an adult-onset neurodegenerative disorder
characterized by the premature loss of upper and lower
motor neurons and is usually fatal within the first 5 years
of disease onset. Over 30 ALS FUS mutations have been
identified; most are missense mutations that are inherited
in an autosomal-dominant fashion and clustered in the
extreme C terminus or the glycine-rich region of FUS.29
FUS is a 526 amino acid RNA binding protein and is
involved inmultiple steps of RNA processing.29 It is mainly
a nuclear protein, but when it is mutated in ALS, it forms
cytoplasmic inclusions in neurons and glial cells.30 Inter-
estingly, the FUS nuclear localization signal (NLS), which
normally targets a protein located in the cytoplasm for
import to the nucleus, is predicted to be located in the
conserved C terminus of the protein. This is precisely
where the vast majority of ALS mutations cluster; thus, it
is possible that these mutations disrupt the NLS, which
explains the irregular distribution of FUS in the cytoplasm,
a theory recently explored by Ito et al.31 Overall, the mech-
anism by which FUS mutations cause ALS is unknown—
the mutations might gain an aberrant function or toxic
property or lose a particular function. Nonetheless, several
reports are now suggesting that the FUS proteinopathy
underlying ALS is unlikely to involve a loss of the protein’s
function but instead involve the gain of toxic effects.31,32
Only two FUS nonsense mutations have been reported in
ALS, and both affect regions located in the C terminus
(p.Arg495* and p.Gln519*) of the protein and are associ-
ated with an extreme ALS phenotype.15,16 It is importantThe Americto note that FUS truncation mutations have never been re-
ported in control individuals.
The FUSmRNAwith the nonsense mutation (c.868C>T)
that segregates in FET1 appears to be mainly degraded by
NMD, which suggests a loss-of-function disease mecha-
nism. On the other hand, our data suggest that mRNA
from FUS mutant ALS cells escapes NMD, which confirms
that theNMDpathway is not amajor determinant of either
toxicity or expression of ALS FUSmutants.33 These prelim-
inary expression data suggest differences in disease mecha-
nism, but elucidating true disease mechanisms will require
further investigation. ET variant p.Gln290* is located in the
predicted NES of the protein, i.e., amino acids 289–298,
which is a short amino acid sequence that targets the
protein for export from the cell nucleus to the cytoplasm
through the nuclear pore complex (the opposite effect of
a NLS). No ALS mutations have been reported in the NES,
as is the case for the zinc finger domain, where the
p.Pro431Leu variation is located. Additionally, upon anal-
ysis of the RNA-Seq data from Illumina’s Human BodyMap
2.0 project (which was assembled by the Broad Institute
with the program Scripture and the ‘‘Brain_R’’ library), all
FUS isoforms appear to encompass the position of both
ET and ALS mutations; thus, disease-specific isoforms are
not likely to exist. Notably, Fus-knockout mice have been
established and found to die shortly after birth.34 Heterozy-
gous Fusþ/ animals have been reported to be phenotypi-
cally undistinguishable from Fusþ/þ animals;34 however,
Fusþ/ animals were not extensively studied because, in
essence, they were primarily used for the generation of
Fus/ animals. Follow-up studies of Fusþ/ mice are war-
ranted. Interestingly, amotor phenotypehas beenobserved
in a recent publication of a fus-knockout zebrafish.35
Comorbidity of ALS with frontotemporal lobe dementia
(FTD [MIM 600274]) and parkinsonism (PD [MIM
168601]) has suggested that these conditions might share
a common pathogenesis; overlapping FUS mutations
have now been found in individuals with ALS/FTD, FTD
and ALS/PD;33,36 FUS inclusions have also been seen
in FTD-affected individuals.29 Interestingly, individuals
affected by ET have been reported to have an increased
genetic risk of developing Parkinson disease;37 however,
there is no direct link between ET and ALS, although it
might be noteworthy that a rapid voice tremor has been
reported as an extrapyramidal symptom in some cases of
ALS.38 Overall, FUS seems to be a functionally important
protein in neuronal cells.
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